

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/657,914	09/09/2003	Bret A. Ferree	BAF-14802/29	5106
7590 06/28/2005			EXAMINER	
John G. Posa Gifford, Krass, Groh, Sprinkle,			PREBILIC, PAUL B	
Anderson & Citkowski, P.C.			ART UNIT	PAPER NUMBER
280 N. Old Woodward Ave., Suite 400			3738	-
Birmingham, MI 48009-5394			DATE MAILED: 06/28/2005	5

Please find below and/or attached an Office communication concerning this application or proceeding.

			A				
		Application No.	Applicant(s)				
		10/657,914	FERREE, BRET A.				
Office Action Summary		Examiner	Art Unit				
		Paul B. Prebilic	3738				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
THE - External contents of the contents of t	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. Insions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. In period for reply specified above is less than thirty (30) days, a reply operiod for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be to within the statutory minimum of thirty (30) do will apply and will expire SIX (6) MONTHS from cause the application to become ABANDON	imely filed ays will be considered timely. m the mailing date of this communication. ED (35 U.S.C. § 133).				
Status							
.1)🖂	Responsive to communication(s) filed on $\underline{20 \ Ju}$						
′=	This action is FINAL . 2b)⊠ This action is non-final.						
3) 🗌	Since this application is in condition for allowance except for formal matters, prosecution as to the ments is						
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposit	ion of Claims						
4) 🖂	4) Claim(s) <u>1-8 and 10</u> is/are pending in the application.						
	4a) Of the above claim(s) is/are withdrawn from consideration.						
· —	Claim(s) is/are allowed.						
•	Claim(s) <u>1-8 and 10</u> is/are rejected.						
,—	Claim(s) is/are objected to. Claim(s) are subject to restriction and/or election requirement.						
ا (٥	Claim(s) are subject to restriction and/o	r election requirement.	·				
Applicat	ion Papers						
9) The specification is objected to by the Examiner.							
10)	The drawing(s) filed on is/are: a) acc						
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
11)	The oath or declaration is objected to by the	taminer. Note the attached Onic	Le Action of John P10-132.				
Priority	under 35 U.S.C. § 119						
•	Acknowledgment is made of a claim for foreign All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document	s have been received.					
	3. Copies of the certified copies of the prior						
application from the International Bureau (PCT Rule 17.2(a)).							
* See the attached detailed Office action for a list of the certified copies not received.							
Attachmer		" –	(DTO 442)				
1) Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date							
3) 🔲 Infor	mation Disclosure Statement(s) (PTO-1449 or PTO/SB/08)	5) 🔲 Notice of Informa	Patent Application (PTO-152)				
	er No(s)/Mail Date	6) U Other:					

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on June 20, 2005 has been entered.

Claim Objections

Claim10 is objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. Claim 10 appears to be merely a statement of intended use in that it merely states that the components can be located outside an intradiscal space.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim 8 recites the limitation "arthroplasty device" in line 1. There is insufficient antecedent basis for this limitation in the claim.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

Art Unit: 3738

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-7 and 10 are rejected under 35 U.S.C. 102(b) as being anticipated by Cauthen (US 6,019,792). Cauthen anticipates the claim language where the bioresorbable components are the endcaps (90) of Cauthen, and the artificial disc replacement as claimed is the implant (10); see the abstract and Figure 2.

With regard to claim 2, the endcap (90) of Figure 2 is considered to be a plate to the extent that this term limits the claim language.

With regard to claims 3-7, the claimed features are considered to be inherent since all solid materials would have these properties to some extent. Additionally, the endcap would inherently limit the degree of motion until it is resorbed.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claim 8 is rejected under 35 U.S.C. 103(a) as being unpatentable over Cauthen (US 6,019,792) in view of Nicholson et al (US 6,096,080). Cauthen meets the claim language as explained in the Section 102 rejection, but fails to disclose using allograft material; see column 4, lines 60-65. However, Nicholson teaches using materials similar to Cauthen as well as allograft material to make a similar disc implant was known; see column 9, lines 42-52. Therefore, it is the Examiner's position that it would

Art Unit: 3738

have been obvious to use at least some allograft as the implant material of Cauthen for the same reasons that Nicholson uses the same; see column 10, line 59 to column 11, line 17 of Nicholson.

Response to Arguments

Applicant's arguments with respect to the claims have been considered but are moot in view of the new ground(s) of rejection.

Conclusion

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

Applicant should specifically point out the support for any amendments made to the disclosure, including the claims (MPEP 714.02 and 2163.06). Due to the procedure outlined in MPEP 2163.06 for interpreting claims, it is noted that other art may be applicable under 35 USC 102 of 35 USC 103(a) once the aforementioned issue(s) is/are addressed.

Applicant is respectfully requested to provide a list of all copending applications that set forth similar subject matter to the present claims. A copy of such copending claims is respectfully requested in response to this Office action if the application is not stored in image format (i.e. the IFW system) or published.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Paul B. Prebilic whose telephone number is (571) 272-4758. He can normally be reached on 6:30-5:00 M-Th.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, McDermott Corrine can be reached on 571-272-4754. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Paul B. Prebilic Primary Examiner

Page 4